296 related articles for article (PubMed ID: 31629006)
1. Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.
Davies SS; May-Zhang LS; Boutaud O; Amarnath V; Kirabo A; Harrison DG
Pharmacol Ther; 2020 Jan; 205():107418. PubMed ID: 31629006
[TBL] [Abstract][Full Text] [Related]
2. Inflammation Biomarker Response to Oral 2-Hydroxybenzylamine (2-HOBA) Acetate in Healthy Humans.
Rathmacher JA; Fuller JC; Abumrad NN; Flynn CR
Inflammation; 2023 Aug; 46(4):1343-1352. PubMed ID: 36935449
[TBL] [Abstract][Full Text] [Related]
3. Isolevuglandins (isoLGs) as toxic lipid peroxidation byproducts and their pathogenetic role in human diseases.
Aschner M; Nguyen TT; Sinitskii AI; Santamaría A; Bornhorst J; Ajsuvakova OP; da Rocha JBT; Skalny AV; Tinkov AA
Free Radic Biol Med; 2021 Jan; 162():266-273. PubMed ID: 33099003
[TBL] [Abstract][Full Text] [Related]
4. Isolevuglandins Promote Mitochondrial Dysfunction and Electrophysiologic Abnormalities in Atrial Cardiomyocytes.
Subati T; Yang Z; Murphy MB; Stark JM; Trykall DZ; Davies SS; Barnett JV; Murray KT
Cells; 2024 Mar; 13(6):. PubMed ID: 38534327
[TBL] [Abstract][Full Text] [Related]
5. Modification by isolevuglandins, highly reactive γ-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function.
May-Zhang LS; Yermalitsky V; Huang J; Pleasent T; Borja MS; Oda MN; Jerome WG; Yancey PG; Linton MF; Davies SS
J Biol Chem; 2018 Jun; 293(24):9176-9187. PubMed ID: 29712723
[TBL] [Abstract][Full Text] [Related]
6. Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation.
Mayorov V; Uchakin P; Amarnath V; Panov AV; Bridges CC; Uzhachenko R; Zackert B; Moore CS; Davies S; Dikalova A; Dikalov S
Redox Biol; 2019 Sep; 26():101300. PubMed ID: 31437812
[TBL] [Abstract][Full Text] [Related]
7. Isolevuglandins and cardiovascular disease.
Davies SS; May-Zhang LS
Prostaglandins Other Lipid Mediat; 2018 Nov; 139():29-35. PubMed ID: 30296489
[TBL] [Abstract][Full Text] [Related]
8. Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr
Tao H; Huang J; Yancey PG; Yermalitsky V; Blakemore JL; Zhang Y; Ding L; Zagol-Ikapitte I; Ye F; Amarnath V; Boutaud O; Oates JA; Roberts LJ; Davies SS; Linton MF
Nat Commun; 2020 Aug; 11(1):4084. PubMed ID: 32796843
[TBL] [Abstract][Full Text] [Related]
9. Scavenging Reactive Lipids to Prevent Oxidative Injury.
May-Zhang LS; Kirabo A; Huang J; Linton MF; Davies SS; Murray KT
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():291-308. PubMed ID: 32997599
[TBL] [Abstract][Full Text] [Related]
10. Scavenging 4-Oxo-2-nonenal.
Amarnath V; Amarnath K
Chem Res Toxicol; 2015 Oct; 28(10):1888-90. PubMed ID: 26355561
[TBL] [Abstract][Full Text] [Related]
11. Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro.
Longato L; Andreola F; Davies SS; Roberts JL; Fusai G; Pinzani M; Moore K; Rombouts K
Free Radic Biol Med; 2017 Jan; 102():162-173. PubMed ID: 27890721
[TBL] [Abstract][Full Text] [Related]
12. Chemistry and analysis of HNE and other prominent carbonyl-containing lipid oxidation compounds.
Sousa BC; Pitt AR; Spickett CM
Free Radic Biol Med; 2017 Oct; 111():294-308. PubMed ID: 28192230
[TBL] [Abstract][Full Text] [Related]
13. Prooxidant-initiated lipid peroxidation in isolated rat hepatocytes: detection of 4-hydroxynonenal- and malondialdehyde-protein adducts.
Hartley DP; Kroll DJ; Petersen DR
Chem Res Toxicol; 1997 Aug; 10(8):895-905. PubMed ID: 9282839
[TBL] [Abstract][Full Text] [Related]
14. Hormetic and regulatory effects of lipid peroxidation mediators in pancreatic beta cells.
Maulucci G; Daniel B; Cohen O; Avrahami Y; Sasson S
Mol Aspects Med; 2016 Jun; 49():49-77. PubMed ID: 27012748
[TBL] [Abstract][Full Text] [Related]
15. U-101033E (2,4-diaminopyrrolopyrimidine), a potent inhibitor of membrane lipid peroxidation as assessed by the production of 4-hydroxynonenal, malondialdehyde, and 4-hydroxynonenal--protein adducts.
Rohn TT; Nelson LK; Waeg G; Quinn MT
Biochem Pharmacol; 1998 Nov; 56(10):1371-9. PubMed ID: 9825737
[TBL] [Abstract][Full Text] [Related]
16. Biological effect of protein modifications by lipid peroxidation products.
Gęgotek A; Skrzydlewska E
Chem Phys Lipids; 2019 Jul; 221():46-52. PubMed ID: 30922835
[TBL] [Abstract][Full Text] [Related]
17. Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls.
Singh M; Kapoor A; Bhatnagar A
Chem Biol Interact; 2015 Jun; 234():261-73. PubMed ID: 25559856
[TBL] [Abstract][Full Text] [Related]
18. Simplified LC/MS assay for the measurement of isolevuglandin protein adducts in plasma and tissue samples.
Yermalitsky VN; Matafonova E; Tallman K; Li Z; Zackert W; Roberts LJ; Amarnath V; Davies SS
Anal Biochem; 2019 Feb; 566():89-101. PubMed ID: 30458125
[TBL] [Abstract][Full Text] [Related]
19. Direct characterization of protein adducts of the lipid peroxidation product 4-hydroxy-2-nonenal using electrospray mass spectrometry.
Bruenner BA; Jones AD; German JB
Chem Res Toxicol; 1995 Jun; 8(4):552-9. PubMed ID: 7548735
[TBL] [Abstract][Full Text] [Related]
20. Isolevuglandins as a gauge of lipid peroxidation in human tumors.
Yan HP; Roberts LJ; Davies SS; Pohlmann P; Parl FF; Estes S; Maeng J; Parker B; Mernaugh R
Free Radic Biol Med; 2017 May; 106():62-68. PubMed ID: 28189846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
